OS Therapies Incorporated
AMEX:OSTXBiotechnology
+$0.10 today
- Market cap
- $53.83M
- Beta
- -0.95
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$0.91
Volume 0.50M
Average 0.71M
OSTX Total Non-current Liabilities
All obligations due after more than one year.
OS Therapies IncorporatedAMEX: OSTX
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 1070.7% from a year ago
Total non-current liabilities stood at $1.17M at the end of Q1 FY2026, up 1070.7% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at -53.9% a year.
Context
- Total non-current liabilities amounted to 16.0% of total assets at the end of Q1 FY2026, up 13.7 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +1070.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.17M USD
- Year-over-year change
- +1070.7%
- 4-year CAGR
- -38.7%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.17M | +1070.7% |
| FY2024 | 2024-12-31 | 100K | +0.0% |
| FY2023 | 2023-12-31 | 100K | -99.2% |
| FY2022 | 2022-12-31 | 11.92M | +43.9% |
| FY2021 | 2021-12-31 | 8.28M | — |
Total Non-current Liabilities vs competitors
How OSTX compares with its peers on the latest reported figures
- OSTX's Mar 2026 total non-current liabilities of $1.17M is the 5th highest of the 9 companies compared; the peer median is $5.14M.
- Its year-over-year change of +1070.7% is the 3rd highest of 8, against a peer median of +13.2%.
- Total non-current liabilities amounts to 16.0% of total assets for OSTX, versus a peer median of 10.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $17.74M | +3070.2% | +7.6% | 22.7% | |
| Mar 2026 | $15.78M | +13.2% | +18.9% | 152.0% | |
| Mar 2026 | $12M | -55.1% | +332.2% | 54.8% | |
| Mar 2026 | $9.73M | +1377.1% | -55.4% | 17.3% | |
OSTXOS Therapies Incorporated | Mar 2026 | $1.17M | +1070.7% | -53.9% | 16.0% |
| Mar 2026 | $543K | — | -51.9% | 4.6% | |
| Mar 2026 | $251K | +68.5% | -70.9% | 0.4% | |
| Jun 2026 | $0 | -100.0% | -15.3% | 0.0% | |
| Mar 2026 | $0 | -100.0% | -37.3% | 0.0% | |
| Peer median (excluding OSTX) | $5.14M | +13.2% | -26.3% | 10.9% | |
Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 80.79K | 171.48K | 38.98K | 5.53M | 269.83M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 231.07K | 1.15K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 956K | 324.21K | 751.05K | 0 | (269.56M) |
| Total Current Assets | 312.82K | 496.84K | 790.03K | 5.53M | 332.91K |
| Property, Plant & Equipment (Net) | 13.08K | 12.27K | 8.05K | 5.27K | 2.49M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 6.5M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | (0) | (2.49M) |
| Total Non-current Assets | 13.08K | 12.27K | 8.05K | 5.27K | 6.51M |
| Total Assets | 325.89K | 509.11K | 798.08K | 5.54M | 6.84M |
| Account Payables | 856.52K | 1.23M | 2.72M | 1.66M | 9.94M |
| Short-term Debt | 0 | 0 | 14.61M | 0 | 0 |
| Tax Payables | 367.02K | 426.01K | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.61M | 3.04M | 4.71M | 2.35M | 0 |
| Total Current Liabilities | 3.5M | 6.15M | 24.71M | 4.63M | 11.76M |
| Long-term Debt | 7.07M | 10.35M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 100K | 100K | 100K | 0 | 100K |
| Other Non-current Liabilities | 1.11M | 1.47M | 100K | 100K | 1.07M |
| Total Non-current Liabilities | 8.28M | 11.92M | 100K | 100K | 1.17M |
| Total Liabilities | 11.78M | 18.07M | 24.81M | 4.73M | 12.94M |
| Common Stock | 9.98K | 4.99K | 5.34K | 20.87K | 37.12K |
| Retained Earnings | (15.22M) | (21.6M) | (29.52M) | (40.4M) | (67.19M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | (0) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (11.45M) | (17.56M) | (24.02M) | 811.49K | (6.1M) |
| Total Debt | 7.07M | 10.35M | 14.61M | 0 | 0 |
| Net Debt | 6.99M | 10.18M | 14.57M | (5.53M) | (269.83M) |
OS Therapies Incorporated
AMEX:OSTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.